Concord Biotech Limited — Investor Meet, 18-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Concord Biotech reported Q3 FY26 revenue up 14% YoY to INR 278 Cr, despite a 5% decline in 9M revenues due to H1 challenges like US tariff uncertainty and EU market supply delays. Core EBITDA margins remained strong at ~40% (ex-start-up costs). Management expects a stronger Q4 and FY27 to normalize towards historical growth (18% CAGR+). Key growth drivers include the WHO GMP-certified injectable facility (INR 600 Cr potential), new anti-infective launches, and CDMO opportunities. The company holds INR 350 Cr in cash and is evaluating inorganic growth. Sentiment remains optimistic for future growth.